CA3132834A1 - Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions - Google Patents
Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions Download PDFInfo
- Publication number
- CA3132834A1 CA3132834A1 CA3132834A CA3132834A CA3132834A1 CA 3132834 A1 CA3132834 A1 CA 3132834A1 CA 3132834 A CA3132834 A CA 3132834A CA 3132834 A CA3132834 A CA 3132834A CA 3132834 A1 CA3132834 A1 CA 3132834A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- poziotinib
- exon
- mutations
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826758P | 2019-03-29 | 2019-03-29 | |
| US62/826,758 | 2019-03-29 | ||
| PCT/US2020/025478 WO2020205632A1 (en) | 2019-03-29 | 2020-03-27 | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3132834A1 true CA3132834A1 (en) | 2020-10-08 |
Family
ID=72666271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3132834A Pending CA3132834A1 (en) | 2019-03-29 | 2020-03-27 | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12629375B2 (en) | 2019-03-29 | 2026-05-19 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions |
| JP7709384B2 (ja) * | 2019-04-17 | 2025-07-16 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物 |
| UY39593A (es) * | 2020-12-29 | 2022-07-29 | Spectrum Pharmaceuticals Inc | Tratamiento para tumores sólidos malignos |
| EP4568994A1 (en) * | 2022-08-09 | 2025-06-18 | Heligenics, Inc. | Method for evaluating clinical relevance of genetic variance |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2005026150A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| MX2007009265A (es) | 2005-02-04 | 2007-09-07 | Boehringer Ingelheim Int | Uso de inhibidores de tirosina quinasa para el tratamiento de rinosinusitis cronica. |
| CA2601936C (en) | 2005-02-24 | 2014-06-17 | Amgen Inc. | Epidermal growth factor receptor mutations |
| CN101351563A (zh) | 2005-10-05 | 2009-01-21 | 阿斯利康(英国)有限公司 | 用于预测或监测病人对于ErbB受体药物的响应的方法 |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| KR101217526B1 (ko) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| US9738935B2 (en) | 2011-11-10 | 2017-08-22 | Roche Molecular Systems, Inc. | Complex mutations in the epidermal growth factor receptor kinase domain |
| EP3603678A3 (en) * | 2011-12-14 | 2020-07-29 | The Board of Regents of the University of Texas System | Collateral gene inactivation biomarkers and targets for cancer therapy |
| AU2013355260B2 (en) | 2012-12-04 | 2019-07-25 | Caris Mpi, Inc. | Molecular profiling for cancer |
| US20180057603A1 (en) | 2013-08-09 | 2018-03-01 | The Trustees Of The University Of Pennsylvania | Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers |
| TWI603971B (zh) | 2013-08-22 | 2017-11-01 | Taiho Pharmaceutical Co Ltd | Novel quinoline substituted compounds |
| EP3699589A1 (en) | 2014-12-12 | 2020-08-26 | Celcuity Inc. | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients |
| CN107250108B (zh) | 2015-02-05 | 2020-11-27 | 特尔诺沃有限公司 | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 |
| CN107530434A (zh) | 2015-04-23 | 2018-01-02 | 免疫医疗有限公司 | 非小细胞肺癌egfr突变阳性的联合疗法 |
| US10308658B2 (en) | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
| EP3458064A1 (en) | 2016-05-18 | 2019-03-27 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
| CN109789204A (zh) * | 2016-05-31 | 2019-05-21 | 雀巢产品技术援助有限公司 | 基于her2和her3通路亚型选择乳癌患者药物疗法的方法 |
| BR112019010020A2 (pt) | 2016-11-17 | 2019-08-20 | Univ Texas | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 |
| EP3585389A4 (en) | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
| WO2018213770A1 (en) | 2017-05-19 | 2018-11-22 | Regents Of The University Of Minnesota | Therapeutic methods |
| CA3076915A1 (en) | 2017-09-27 | 2019-04-04 | AI Therapeutics, Inc. | Therapeutic methods relating to hsp90 inhibitors |
| KR20190054826A (ko) | 2017-11-14 | 2019-05-22 | 한미약품 주식회사 | 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도 |
| JP7386174B2 (ja) | 2018-03-27 | 2023-11-24 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
| US20210235688A1 (en) | 2018-04-19 | 2021-08-05 | Board Of Regents, The University Of Texas System | Methods for measuring and stabilizing stat3 inhibitors |
| SG11202012064PA (en) | 2018-06-25 | 2021-01-28 | Spectrum Pharmaceuticals Inc | Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof |
| CA3098204A1 (en) | 2018-06-25 | 2020-01-02 | Spectrum Pharmaceuticals, Inc. | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof |
| KR20210066819A (ko) | 2018-09-04 | 2021-06-07 | 레인 세러퓨틱스 인코포레이티드 | Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법 |
| KR20210107023A (ko) * | 2018-12-21 | 2021-08-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료를 위한 조합 요법 |
| WO2020150208A1 (en) | 2019-01-14 | 2020-07-23 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors |
| US12679855B2 (en) | 2019-01-27 | 2026-07-14 | Board Of Regents, The University Of Texas System | Inhibitors of the enzyme enolase for precision oncology |
| WO2020172485A1 (en) | 2019-02-22 | 2020-08-27 | Board Of Regents, The University Of Texas System | Methods of using imipridones |
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| US20200299783A1 (en) | 2019-03-18 | 2020-09-24 | Board Of Regents, The University Of Texas System | Molecular signature for selecting lymphoma patients for treatment with ibrutinib |
| WO2020198633A1 (en) | 2019-03-27 | 2020-10-01 | Board Of Regents, The University Of Texas System | Nuclear-derived exosomes and methods of use thereof |
| WO2020205646A2 (en) | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Small molecule parg inhibitors and methods of use thereof |
| US12629375B2 (en) | 2019-03-29 | 2026-05-19 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions |
| US20220143023A1 (en) | 2019-03-29 | 2022-05-12 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
| JP7709384B2 (ja) | 2019-04-17 | 2025-07-16 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物 |
| JP7822597B2 (ja) | 2019-04-17 | 2026-03-03 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | チロシンキナーゼ阻害剤耐性egfr変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
| KR102477643B1 (ko) * | 2019-05-09 | 2022-12-13 | 주식회사 엘지에너지솔루션 | 전기화학소자용 분리막 및 이를 포함하는 전기화학소자 |
| WO2020251965A1 (en) | 2019-06-10 | 2020-12-17 | Board Of Regents, The University Of Texas System | Combinatorial therapy targeting parp1 and rtk |
| US20220356467A1 (en) | 2019-06-25 | 2022-11-10 | Board Of Regents, The University Of Texas System | Methods for duplex sequencing of cell-free dna and applications thereof |
-
2020
- 2020-03-27 US US17/600,017 patent/US12629375B2/en active Active
- 2020-03-27 CN CN202080032340.6A patent/CN113766955A/zh active Pending
- 2020-03-27 MX MX2021011925A patent/MX2021011925A/es unknown
- 2020-03-27 KR KR1020217032121A patent/KR20210145161A/ko active Pending
- 2020-03-27 JP JP2021557941A patent/JP7700043B2/ja active Active
- 2020-03-27 WO PCT/US2020/025478 patent/WO2020205632A1/en not_active Ceased
- 2020-03-27 PH PH1/2021/552110A patent/PH12021552110A1/en unknown
- 2020-03-27 CA CA3132834A patent/CA3132834A1/en active Pending
- 2020-03-27 AU AU2020256119A patent/AU2020256119A1/en not_active Abandoned
- 2020-03-27 SG SG11202109531UA patent/SG11202109531UA/en unknown
- 2020-03-27 BR BR112021019376A patent/BR112021019376A2/pt not_active Application Discontinuation
- 2020-03-27 EP EP20782979.7A patent/EP3946632A4/en active Pending
-
2021
- 2021-09-22 IL IL286576A patent/IL286576A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210145161A (ko) | 2021-12-01 |
| WO2020205632A1 (en) | 2020-10-08 |
| US20220175778A1 (en) | 2022-06-09 |
| PH12021552110A1 (en) | 2022-06-06 |
| CN113766955A (zh) | 2021-12-07 |
| WO2020205632A8 (en) | 2021-10-14 |
| AU2020256119A1 (en) | 2021-10-07 |
| US12629375B2 (en) | 2026-05-19 |
| EP3946632A1 (en) | 2022-02-09 |
| IL286576A (en) | 2021-12-01 |
| JP2022527499A (ja) | 2022-06-02 |
| EP3946632A4 (en) | 2023-01-04 |
| MX2021011925A (es) | 2021-11-03 |
| JP7700043B2 (ja) | 2025-06-30 |
| BR112021019376A2 (pt) | 2021-12-07 |
| SG11202109531UA (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230233563A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations | |
| US20250312348A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions | |
| US20220175779A1 (en) | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations | |
| US20210015819A1 (en) | Methods for treatment of cancers with egfr activating mutations | |
| US12629375B2 (en) | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions | |
| EP3773551B1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
| JP7564806B2 (ja) | がんの処置のための併用療法 | |
| HK40064724A (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240327 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250208 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250219 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251016 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20260216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260508 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260805 |